Symptom-triggered alcohol vapor inhalation for postoperative alcohol withdrawal syndrome in patients with gastroesophageal carcinoma.
The purpose of this study was to investigate the feasibility and efficacy of alcohol vapor inhalation during fasting time for cancer patients with alcohol withdrawal symptoms (AWS) after surgery. The data of 51 patients after esophagectomy or gastrectomy for gastroesophageal carcinoma in two hospitals from January 2011 to December 2016 was retrospectively analyzed. These patients were diagnosed with AWS with Clinic Institute Alcohol Withdrawal Syndrome Scale (CIWA-Ar) score ≥ 9 in two hospitals during fasting time from January 2011 to December 2016, and they were accordingly divided into alcohol vapor group (n=25) and diazepam group (n=26). As oral intake of wine was forbidden in the first 7 postoperative days, these patients received either alcohol vapor inhalation or intravenous administration of diazepam every 12 hrs. The difference in scores of CIWA-Ar, Riker Sedation-Agitation Scale (SAS), side effects and complications were registered and analyzed. The patients in both groups gained satisfactory efficacy which was indicated by CIWA-Ar scores after therapy, without obvious difference in terms of surgery-related complications, chest and abdominal drainage, serum biomarkers of hepatic function or postoperative hospital stay. However, the patients treated with alcohol vapor inhalation displayed lower alcohol craving and sleepiness, more significant decreased CIWA-Ar scores, as well as encouragingly higher degree of satisfaction, comparing with the diazepam group. Alcohol vapor inhalation is feasible and effective to alleviate AWS timely, which is reliable for patients to get through the fasting time after surgery.